PURPOSE: To examine the rates and risk factors for radiation pneumonitis (RP) in non-small-cell lung cancer (NSCLC) patients treated with chemoradiotherapy. METHODS AND MATERIALS: We reviewed dosimetry records from Stage III NSCLC patients treated on a prospective randomized trial. Patients received concurrent cisplatinum/etoposide with radiation therapy to 59.4 Gy. A total of 243 patients were enrolled; 167 did not experience progression and were randomized toobservation (OB) or consolidation docetaxel (CD). Toxicity was coded based on the presence of Grade 0 to 1 vs. Grade 2 to 5 RP using the Common Toxicity Criteria and Adverse Events (CTCAE) v3.0. RESULTS: Median age and follow-up were 63 years and 16 months, respectively. Overall, Grade 0 to 1 and Grade 2 to 5 RP were reported in 226 patients and 17 patients (7%) respectively. Median mean lung dose (MLD), V5, V20, and V30 for evaluable patients were 18 Gy, 52%, 35%, and 29%. MLD in Grade 0 to 1 and Grade 2 to 5 patients was 1,748 c Gy and 2,013 cGy in respectively (p = 0.12). Grade 2 to 5 RP developed in 2.2% and 19% of patients with MLD < 18 Gy and MLD > 18 Gy, respectively (p = 0.015). Mean V20 was 33.7% and 37.7% for Grade 0 to 1 and Grade 2 to 5 groups, respectively (p = 0.29). Grade 2 to 5 RP developed in 4.8% and 17% of patients with V20 < 35% and V20 > 35%, respectively. The OB and CD groups had similar MLD and V20, and the RP rates were 3.6% and 14.6%, respectively (p = 0.015). Patients who developed Grade 0 to 1 and Grade 2 to 5 RP had similar mean V5, V10, V15, V20, V25, V30, age, smoking history, and tumor characteristics. CONCLUSIONS: The overall rate of Grade 2 to 5 RP was 7% in patients treated with chemoradiotherapy. In this analysis, predictive factors for RP were MLD > 18 Gy and treatment with CD.
RCT Entities:
PURPOSE: To examine the rates and risk factors for radiation pneumonitis (RP) in non-small-cell lung cancer (NSCLC) patients treated with chemoradiotherapy. METHODS AND MATERIALS: We reviewed dosimetry records from Stage III NSCLCpatients treated on a prospective randomized trial. Patients received concurrent cisplatinum/etoposide with radiation therapy to 59.4 Gy. A total of 243 patients were enrolled; 167 did not experience progression and were randomized to observation (OB) or consolidation docetaxel (CD). Toxicity was coded based on the presence of Grade 0 to 1 vs. Grade 2 to 5 RP using the Common Toxicity Criteria and Adverse Events (CTCAE) v3.0. RESULTS: Median age and follow-up were 63 years and 16 months, respectively. Overall, Grade 0 to 1 and Grade 2 to 5 RP were reported in 226 patients and 17 patients (7%) respectively. Median mean lung dose (MLD), V5, V20, and V30 for evaluable patients were 18 Gy, 52%, 35%, and 29%. MLD in Grade 0 to 1 and Grade 2 to 5 patients was 1,748 c Gy and 2,013 cGy in respectively (p = 0.12). Grade 2 to 5 RP developed in 2.2% and 19% of patients with MLD < 18 Gy and MLD > 18 Gy, respectively (p = 0.015). Mean V20 was 33.7% and 37.7% for Grade 0 to 1 and Grade 2 to 5 groups, respectively (p = 0.29). Grade 2 to 5 RP developed in 4.8% and 17% of patients with V20 < 35% and V20 > 35%, respectively. The OB and CD groups had similar MLD and V20, and the RP rates were 3.6% and 14.6%, respectively (p = 0.015). Patients who developed Grade 0 to 1 and Grade 2 to 5 RP had similar mean V5, V10, V15, V20, V25, V30, age, smoking history, and tumor characteristics. CONCLUSIONS: The overall rate of Grade 2 to 5 RP was 7% in patients treated with chemoradiotherapy. In this analysis, predictive factors for RP were MLD > 18 Gy and treatment with CD.
Authors: Raymond H Mak; Brian M Alexander; Kofi Asomaning; Rebecca S Heist; Chen-yu Liu; Li Su; Rihong Zhai; Marek Ancukiewicz; Brian Napolitano; Andrzej Niemierko; Henning Willers; Noah C Choi; David C Christiani Journal: Cancer Date: 2011-12-05 Impact factor: 6.860
Authors: David A Palma; Suresh Senan; Kayoko Tsujino; Robert B Barriger; Ramesh Rengan; Marta Moreno; Jeffrey D Bradley; Tae Hyun Kim; Sara Ramella; Lawrence B Marks; Luigi De Petris; Larry Stitt; George Rodrigues Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-09 Impact factor: 7.038
Authors: Stephen G Chun; Chen Hu; Hak Choy; Ritsuko U Komaki; Robert D Timmerman; Steven E Schild; Jeffrey A Bogart; Michael C Dobelbower; Walter Bosch; James M Galvin; Vivek S Kavadi; Samir Narayan; Puneeth Iyengar; Clifford G Robinson; Raymond B Wynn; Adam Raben; Mark E Augspurger; Robert M MacRae; Rebecca Paulus; Jeffrey D Bradley Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544
Authors: Gurleen Dhami; Jing Zeng; Hubert J Vesselle; Paul E Kinahan; Robert S Miyaoka; Shilpen A Patel; Ramesh Rengan; Stephen R Bowen Journal: Strahlenther Onkol Date: 2017-03-02 Impact factor: 3.621
Authors: Matthew R McCurdy; Richard Castillo; Josue Martinez; Mohammad Najeeb Al Hallack; Jessica Lichter; Nicolas Zouain; Thomas Guerrero Journal: Radiother Oncol Date: 2012-05-10 Impact factor: 6.280